Cyclacel Pharmaceuticals (CYCC) Makes Enemies Of Shareholders
Cyclacel Pharmaceuticals (CYCC) is selling down 11% on poor earnings and could drop below $1. CYCC announced financial and operating results for the second quarter of 2009. The firm’s net loss for the...
View ArticleCyclacel Pharmaceuticals (CYCC) Rise Looks Bogus
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is up after BeaconEquity.com announces a video investment report featuring the company. There is nothing new about CYCC and it would appear that the promotion is...
View Article10-Bagger Watch: Cyclacel Meets Biotech Trophy Hunters (CYCC)
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was the latest example of trader, speculators and investors running out to pile into the next low-price small cap biotech stock in the quest for the...
View ArticleCyclacel Pharmaceuticals (CYCC) Pounded
Cyclacel (NASDAQ:CYCC) disclosed that it has entered into definitive agreements to raise $7.2 million in gross proceeds, before deducting placement agent fees and other estimated offering expenses,...
View ArticleGenVec Shows Again the Risks of Biotech Trophy Hunting (GNVC, ROSG, MRNA, CYCC)
We have covered over and over in recent months about the news flow of biotech and emerging biohealth companies creating an avenue that is causing traders to chase many speculative stocks up...
View ArticleCyclacel Up More Than 20%
BioCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) has successfully negotiated a trial structure with the FDA for their experimental leukemia drug. Shares of CYCC are up %12.1 to $1.76, with most of the...
View ArticleClik here to view.
Outlook 2011: 2010 BioHealth Winners Part 1 (ARIA, CHTP, CYCC, ENMD, EXAS,...
2010 has so far lacked all of the juice that drove many biotech stocks exponentially higher in 2009. For starters, the start of this year was not initiated with a deadly round of panic selling and...
View Article
